These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9019836)

  • 1. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].
    Eliseev OM
    Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836
    [No Abstract]   [Full Text] [Related]  

  • 2. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
    Labrid C
    Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine].
    Kalinina EB; Komissarova IA; Zaslavskaia RM; Zhdanov IuA
    Klin Med (Mosk); 2002; 80(5):50-3. PubMed ID: 12087889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of trimetazidine for out of hospital physical rehabilitation after myocardial infarction].
    Aronov DM; Tartakovskiĭ LB; Novikova NK; Pisareva NA; Smolenskiĭ VS; Zhidko NI
    Kardiologiia; 2002; 42(11):14-20. PubMed ID: 12494029
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic treatment of myocardial ischaemia.
    Ferrari R
    Eur Heart J; 1999 Aug; 20(16):1144-5. PubMed ID: 10448019
    [No Abstract]   [Full Text] [Related]  

  • 6. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myocardial cytoprotection with trimetazidine in patients with ischemic heart disease during surgical stress].
    Afanas'eva IV; Goncharova LL; Miroshnichenko AG; Petrash VV; Pokrovskaia LA
    Vestn Khir Im I I Grek; 1999; 158(5):34-7. PubMed ID: 10645577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
    Rosano GM; Marazzi G; Patrizi R; Cerquetani E; Vitale C; Volterrani M; Fini M; Mercuro G
    Am J Cardiol; 2005 Feb; 95(3):327-31. PubMed ID: 15670539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E; McMurray JJ
    Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
    Rizzon P; Iliceto S; Marangelli V
    Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD
    Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can metabolic manipulation reverse myocardial dysfunction?
    Cokkinos DV
    Eur Heart J; 2001 Dec; 22(23):2138-9. PubMed ID: 11913472
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
    Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus].
    Petriĭ VV; Mikova NV; Makolkin VI
    Kardiologiia; 2007; 47(7):22-5. PubMed ID: 18260890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angina, myocardial hibernation and trimetazidine.
    Jackson G
    Int J Clin Pract; 1997 Sep; 51(6):347. PubMed ID: 9489058
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
    Churshin AD; Pimenov LT
    Kardiologiia; 2003; 43(8):31-5. PubMed ID: 14593380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.